The global market for therapeutic peptides reached $42 billion in 2023. Péptidos Costa Rica, founded by two American entrepreneurs, bets on education and transparency to compete in a sensitive sector.
The global market for therapeutic peptides reached $42 billion in 2023 and is expected to double to $81 billion by 2030, with an annual growth rate of 9.8%. In this context, a Costa Rican startup is demonstrating that educational content can be the key to breaking into a highly specialised scientific niche.
Péptidos Costa Rica is a company that provides synthetic peptides for scientific research, operating exclusively within Costa Rican territory. It was founded by Sean McCully and Joey Webster, two entrepreneurs who moved from California to Costa Rica over 15 years ago, with experience in combat sports and high-performance training.
Their value proposition focuses on solving the typical frictions of buying scientific products from abroad: customs delays, stock uncertainty, lack of communication, and logistical complexity. While a Costa Rican researcher might wait weeks importing from the United States or Europe, this startup offers local delivery, communication in Spanish, and accessible after-sales support.
The difference lies not in the product itself, but in the complete purchasing experience. The company has developed a strategy of educational content that builds trust before the sale, something crucial in a sector where regulation and scientific evidence are sensitive.
The content funnel follows a classic scientific B2B structure. At the top, explanatory articles about what peptides are and their applications. In the middle, buying guides and technical sheets. At the bottom, clear prices, real-time availability, and direct contact via WhatsApp or phone.
The key is that the content does not sell vague benefits, but rather educates with technical rigor. According to the company's philosophy, a good supplier should offer detailed educational content rather than just product listings with generic benefits.
The rise of peptides in Costa Rica is not without controversy. A report from El Financiero noted that the market is growing driven by influencers and biohacking communities, but clashes against regulatory gaps and limited scientific evidence for certain compounds. Some peptides have scientific backing and health approval, while others are marketed without registration and with insufficient clinical studies.
For Péptidos Costa Rica, this regulatory context means that their content must include clarity about permitted uses, limitations, and available documentation. Trust is not built solely with technical education, but with honesty about the regulatory status of each product.
For the founders of B2B startups in technical or scientific niches in Latin America, this case offers practical lessons. The first: turning logistical friction into a competitive advantage. In emerging markets, poor infrastructure creates opportunities. If competitors are international suppliers with long delivery times, a local approach can be the main differentiator.
The second lesson: transparency about limitations generates more long-term trust than exaggerated promises. In regulated sectors, being clear about what can and cannot be offered is a competitive asset.
Péptidos Costa Rica demonstrates that, in a globalised market, the combination of rigorous educational content and local attention can be the formula to compete with international giants. The startup continues to operate exclusively in Costa Rica, but its content strategy is already a case study for entrepreneurs across the region.
You may also like
